Request for Information on CDC Procurement of Clinical Specimens
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Centers for Disease Control and Prevention (CDC) is issuing a Request for Information (RFI) to gather market research on the procurement of clinical specimens or synthetic specimen matrices. This initiative supports the development and validation of diagnostic tests, aligning with the National Biodefense Strategy to enhance pandemic preparedness and counter biological threats. This RFI is for market research only and does not guarantee a future solicitation or award.
Scope of Information Requested
The CDC seeks comprehensive information on end-to-end solutions for specimen acquisition. Key areas of interest include:
- Approach: Protocols for specimen collection, handling, storage, packaging, transport, and data management (e.g., CSV to Palantir). Compliance with shipping regulations (IATA, DOT, OSHA).
- Specimen Characterization: Details on diagnostic characterization testing performed or available.
- Human Subjects Protection: Compliance with 45 CFR Part 46 and 21 CFR Parts 50/56, including consent procedures.
- Capability & Capacity: Organizational capabilities, available specimen types (including uncommon ones), volumes, lead times, and delivery schedules. Information on synthetic matrices.
- Quality Systems: Systems for ensuring specimen quality, consistency, and traceability (e.g., cold chain, testing documentation).
- Stability Data: Research supporting optimal storage conditions.
- Safety: Confirmation of BSL-2 rated facilities.
- Data Availability: Description of available metadata and ability to provide additional data upon request.
- Expedited Collection: Ability to expedite specimen collection (≤72 hours) during public health emergencies.
- Costs: Rough order of magnitude cost factors and pricing structures.
Contract & Timeline
- Type: Sources Sought / Request for Information (RFI)
- Set-Aside: None specified
- Response Due: May 22, 2026, at 2:00 PM UTC (10:00 AM ET)
- Published: April 23, 2026
Submission Requirements
Responses should not exceed 15 pages, including a cover page. The cover page must include Unique Entity Identification (UEI) numbers, Point of Contact information, Company Name and Address, NAICS code, and business size classification. Proprietary information should be minimized and clearly marked.
Contact Information
For inquiries, contact Joesph Miller at faz9@cdc.gov or 404.639.0279.